KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Non-Current Deffered Revenue (2018 - 2023)

Astrazeneca (AZN) has 1 years of Non-Current Deffered Revenue data on record, last reported at $7.0 million in Q4 2023.

  • For Q4 2023, Non-Current Deffered Revenue changed N/A year-over-year to $7.0 million; the TTM value through Dec 2023 reached $7.0 million, changed N/A, while the annual FY2023 figure was $7.0 million, N/A changed from the prior year.
  • Non-Current Deffered Revenue reached $7.0 million in Q4 2023 per AZN's latest filing.
  • Across five years, Non-Current Deffered Revenue topped out at $7.0 million in Q4 2023 and bottomed at $7.0 million in Q4 2023.